These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24947902)

  • 1. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo.
    Guan SS; Chang J; Cheng CC; Luo TY; Ho AS; Wang CC; Wu CT; Liu SH
    Oncotarget; 2014 Jul; 5(13):4868-80. PubMed ID: 24947902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
    Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo.
    Guan SS; Wu CT; Chiu CY; Luo TY; Wu JY; Liao TZ; Liu SH
    J Transl Med; 2018 Jun; 16(1):168. PubMed ID: 29921305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
    Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
    Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
    Das D; Xie L; Wang J; Shi J; Hong J
    Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
    LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
    Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
    Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
    Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
    Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
    Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
    Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer.
    Yalikong A; Li XQ; Zhou PH; Qi ZP; Li B; Cai SL; Zhong YS
    Int J Nanomedicine; 2021; 16():2323-2335. PubMed ID: 33776436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
    Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
    J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and Activity of EGFR Targeted Polymeric Micelles Delivering a New Inhibitor of DNA Repair to Orthotopic Colorectal Cancer Xenografts with Metastasis.
    de Paiva IM; Vakili MR; Soleimani AH; Tabatabaei Dakhili SA; Munira S; Paladino M; Martin G; Jirik FR; Hall DG; Weinfeld M; Lavasanifar A
    Mol Pharm; 2022 Jun; 19(6):1825-1838. PubMed ID: 35271294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
    Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
    J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.
    Zhang M; Taylor CE; Piao L; Datta J; Bruno PA; Bhave S; Su T; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
    Mol Cancer Ther; 2013 Aug; 12(8):1515-25. PubMed ID: 23723125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
    Xue C; Tian Y; Zhang J; Zhao Y; Zhan J; Fang W; Zhang L
    Drug Des Devel Ther; 2016; 10():1299-306. PubMed ID: 27099475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 activating mutations are targets for colorectal cancer treatment.
    Kavuri SM; Jain N; Galimi F; Cottino F; Leto SM; Migliardi G; Searleman AC; Shen W; Monsey J; Trusolino L; Jacobs SA; Bertotti A; Bose R
    Cancer Discov; 2015 Aug; 5(8):832-41. PubMed ID: 26243863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.